SURMOUNT-5

Definition

The head-to-head everyone wanted: tirzepatide against semaglutide for weight management in non-diabetic adults with obesity (Aronne et al., NEJM 2025, PMID 40353578). Tirzepatide −20.2% against semaglutide −13.7% at 72 weeks, a 6.5-point gap. It is the strongest single argument for paying more for tirzepatide, and sellers of both cite it.

SURMOUNT-5 trial deep-dive →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under trial

• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• SURMOUNT-5 trial deep-dive
• The full GLP-1 glossary (149 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers